The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Predictors of outcomes in post-transplant patients with AML
Justin Ching Ting Loke, BM BCh, PhD, University of Birmingham, Birmingham, UK, discusses post-transplant minimal residual disease (MRD) monitoring of patients with acute myeloid leukemia (AML) in the Phase II FIGARO trial (EudraCT: 2012-005538-12). Whilst the pre-transplant AML status has prognostic value, post-transplant MRD monitoring remains invaluable in patient management. Additional predictors of outcomes include T-cell chimerism, where patients with mixed-donor T-cell chimerism (MDTC) had inferior overall survival rates. Downregulation of human leukocyte antigens (HLA) on leukemic blasts is also associated with increased rates of relapse. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
